Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies, such as therapeutic autologous lymphocytes, may stimulate
the immune system in different ways and stop tumor cells from growing. Drugs used in
chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Cyclophosphamide may
also stimulate the immune system in different ways and stop tumor cells from growing.
Aldesleukin may stimulate white blood cells to kill tumor cells. Giving therapeutic
autologous lymphocytes together with cyclophosphamide and aldesleukin may be an effective
treatment for melanoma.
PURPOSE: This phase I trial is studying the side effects of giving therapeutic autologous
lymphocytes together with cyclophosphamide and aldesleukin in treating patients with stage IV
melanoma
Phase:
Phase 1
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium